Product Data Sheet

APC/Fire™ 750 anti-human HLA-DR

Catalog # / 2235115 / 25 tests

Size: 2235120 / 100 tests

Clone: LN3

Isotype: Mouse IgG2b, κ

Immunogen: human PBL
Reactivity: Human, Other

Preparation: The antibody was purified by affinity

chromatography and conjugated with

APC/Fire™ 750 under optimal

conditions.


Formulation: Phosphate-buffered solution, pH 7.2,

containing 0.09% sodium azide and

0.2% (w/v) BSA (origin USA).

Workshop Number: 750 under optimal conditions.

Concentration: Lot-specific



Human peripheral blood lymphocytes were stained with HLA-DR (clone LN3) APC/Fire™ 750 (filled histogram) or mouse lgG2b, κ APC/Fire™ 750 isotype control (open histogram).

Applications:

Applications: Flow Cytometry

Recommended

Usage:

Each lot of this antibody is quality control tested by immunofluorescent

staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per

100 μl of whole blood.

* APC/Fire™ 750 has a maximum excitation of 650 nm and a maximum

emission of 787 nm.

Application Notes:

Additional reported applications (for the relevant formats) include:

immunohistochemical staining 1 of frozen sections and formalin-fixed paraffin-embedded sections 1 , and


 $immun oprecipitation ^{1}.\\$

Application References:

1. Marder RJ, et al. 1985. Lab. Invest. 52:497.

2. Norton AJ and Isaacson PG. 1987. Am. J. Pathol. 128:225.

3. Hua ZX, et al. 1998. Hum. Pathol. 29(12):1441.



Description:

The LN3 monoclonal antibody reacts with the HLA-DR antigen, a member of MHC class II molecules. HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD α (heavy) chain and a 27 kD β (light) chain. It is expressed on B cells, activated T cells, monocytes/macrophages, dendritic cells and other non-professional APCs. In conjunction with the CD3/TCR complex and CD4 molecules, HLA-DR is critical for efficient peptide presentation to CD4 $^+$ T cells.

Antigen References:

- 1. Levacher M, et al. 1990. Clin. Exp. Immunol. 81:177.
- 2. Terstappen L, et al. 1990. J. Leuk. Biol. 48:138.
- 3. Edwards J, et al. 1985. J. Immunol. 137:490.
- 4. van Es A, et al. 1984. Transplantation 37:65.
- 5. O'Doherty U, et al. 1994. Immunology 82:487.
- 6. Thomas R, et al. 1994. J. Immunol. 153:4016.
- 7. Grouard G, et al. 1996. Nature 384:364.